Diphtheria-Toxin-Based Fusion-Protein Toxins Targeted to the Interleukin-2 Receptor: Unique Probes for Cell Biology and a New Therapeutic Agent for the Treatment of Lymphoma
作者： J. R. Murphy , J. C. Vanderspek
DOI: 10.1007/978-3-662-05971-5_5
关键词:
摘要: ONTAK (denileukin diftitox) is the trade and generic name for diphtheria-toxin-based interleukin-2 (IL-2) fusion-protein toxin DAB389IL-2 (Williams et al. 1987, 1990). The Food Drug Administration has recently granted approval use of treatment patients who present with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells are shown to express low-affinity p55 chain (CD25) IL-2 receptor. Since first rationally designed, targeted toxins be approved human use, we shall, in this chapter, review pre-clinical clinical development biologic discuss agent as a novel probe furthering our understanding molecular mechanism by which catalytic domain translocated cytosol target eukaryotic cells.
springer.com
sci-hub.st 参考文章(60)
CF LeMaistre, C Meneghetti, M Rosenblum, J Reuben, K Parker, J Shaw, A Deisseroth, T Woodworth, DR Parkinson, Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood. ,vol. 79, pp. 2547- 2554 ,(1992) , 10.1182/BLOOD.V79.10.2547.2547
D P Williams, C E Snider, T B Strom, J R Murphy, Structure/function analysis of interleukin-2-toxin (DAB486-IL-2) : fragment B sequences required for the delivery of fragment A to the cytosol of target cells Journal of Biological Chemistry. ,vol. 265, pp. 11885- 11889 ,(1990) , 10.1016/S0021-9258(19)38482-0
D Cassidy, J vanderSpek, P D Huynh, F Genbauffe, J R Murphy, An intact transmembrane helix 9 is essential for the efficient delivery of the diphtheria toxin catalytic domain to the cytosol of target cells. Journal of Biological Chemistry. ,vol. 269, pp. 21455- 21459 ,(1994) , 10.1016/S0021-9258(17)31825-2
James Reuben, David H. Boldt, Michael Rosenblum, Becky McMullin, Karen Parker, Thasia Woodworth, C. F. LeMaistre, Carole Meneghetti, Fiona E. Craig, Phase I Trial of a 90-Minute Infusion of the Fusion Toxin DAB486IL-2 in Hematological Cancers Cancer Research. ,vol. 53, pp. 3930- 3934 ,(1993)
Mark Ratain, C. F. LeMaistre, Cesar O. Freytes, Alain Rook, James Reuben, Gary Schwartz, Francine Foss, Mansoor N. Saleh, Timothy M. Kuzel, Jean C. Nichols, Leonidas C. Platanias, Fiona Craig, Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interkeukin-2 Blood. ,vol. 91, pp. 399- 405 ,(1998) , 10.1182/BLOOD.V91.2.399
D. Michael Gill, A.M. Pappenheimer, Structure-activity relationships in diphtheria toxin. Journal of Biological Chemistry. ,vol. 246, pp. 1492- 1495 ,(1971) , 10.1016/S0021-9258(19)76999-3
P. Aullo, J. Alcami, M.R. Popoff, D.R. Klatzmann, J.R. Murphy, P. Boquet, A recombinant diphtheria toxin related human CD4 fusion protein specifically kills HIV infected cells which express gp120 but selects fusion toxin resistant cells which carry HIV. The EMBO Journal. ,vol. 11, pp. 575- 583 ,(1992) , 10.1002/J.1460-2075.1992.TB05089.X
P Bacha, J R Murphy, S Reichlin, Thyrotropin-releasing hormone-diphtheria toxin-related polypeptide conjugates. Potential role of the hydrophobic domain in toxin entry. Journal of Biological Chemistry. ,vol. 258, pp. 1565- 1570 ,(1983) , 10.1016/S0021-9258(18)33021-7
M Tsuneoka, K Nakayama, K Hatsuzawa, M Komada, N Kitamura, E Mekada, Evidence for involvement of furin in cleavage and activation of diphtheria toxin. Journal of Biological Chemistry. ,vol. 268, pp. 26461- 26465 ,(1993) , 10.1016/S0021-9258(19)74337-3
Rae Drazin, Judith Kandel, R.J. Collier, Structure and activity of diphtheria toxin. II. Attack by trypsin at a specific site within the intact toxin molecule. Journal of Biological Chemistry. ,vol. 246, pp. 1504- 1510 ,(1971) , 10.1016/S0021-9258(19)77001-X